FDA officials are off on a three-week sprint to review J&J COVID-19 vaccine data
Johnson & Johnson released data from its vaccine clinical trial last week. Johnson & Johnson announced yesterday that it had officially asked the Food and Drug Administration to authorize its COVID-19 vaccine, kicking off a process that will send its one-shot immunization through a gauntlet of analysts and experts.
If all goes as expected and the agency agrees that the benefits of the vaccine outweigh the risks, the United States could have a third shot available by the end of February. Experts hope that this vaccine - which only takes one dose and can be stored in the refrigerator - could accelerate the United States' vaccination campaign.
Over the next few weeks, FDA officials will work at breakneck speeds to review the data submitted by Johnson & Johnson. Then, they'll write up a report and submit it to...